Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Clinical role
Radiation-treatment planning, image registration, contouring, dose calculation, or plan review support under qualified professional control.
Images and patients
Radiotherapy Planning Imaging · CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Key limitation
Keep in mind: Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR Input: Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, and other trained radiation-treatment professionals.
What does the software produce?Output: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
What is its most important limitation?Key limitation: Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.
Clinical takeaway. Clinical role: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-inferiority testing against atlases from the MIM Maestro reference device on test subjects from a pool of 754 independent images gathered from 27 institutions totally disjoint from the training datasets, measuring Dice score and MDA against original ground-truth contours. It states results were equivalent or better than the reference device, with equivalence defined as the device's lower 95th percentile confidence bound being greater than 0.1 Dice lower than the reference mean. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Automated contours, plans, registrations, dose values, or other outputs require qualified review, editing, commissioning, and local validation before clinical use.
The exact FDA document reports non-inferiority testing against atlases from the MIM Maestro reference device on test subjects from a pool of 754 independent images gathered from 27 institutions totally disjoint from the training datasets, measuring Dice score and MDA against original ground-truth contours. It states results were equivalent or better than the reference device, with equivalence defined as the device's lower 95th percentile confidence bound being greater than 0.1 Dice lower than the reference mean. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non- inferiority testing was used to compare the proposed Contour ProtégéAI device to Atlases created from the MIM Maestro (K071964) reference device." … "The proposed Contour ProtégéAI device were then evaluated on the test subjects from a pool of 754 independent images gathered from 27 institutions.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-inferiority testing against atlases from the MIM Maestro reference device on test subjects from a pool of 754 independent images gathered from 27 institutions totally disjoint from the training datasets, measuring Dice score and MDA against original ground-truth contours. It states results were equivalent or better than the reference device, with equivalence defined as the device's lower 95th percentile confidence bound being greater than 0.1 Dice lower than the reference mean. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non- inferiority testing was used to compare the proposed Contour ProtégéAI device to Atlases created from the MIM Maestro (K071964) reference device." … "The proposed Contour ProtégéAI device were then evaluated on the test subjects from a pool of 754 independent images gathered from 27 institutions.". Read from the exact FDA decision document on 2026-11-14.
No exact-submission and version-linked sensitivity endpoint is promoted; candidate or product-family values were not substituted.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K231765
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K231765; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K231765; a broader clinical population is not established here.
Scopeexact submission
Tested versionContour ProtégéAI (K231765)
IndependenceSponsor or vendor study
K231765
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT, MR, PET, or other DICOM image data, structures, prescriptions, and treatment-planning inputs within the exact submission.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes processing of CT and MR images as supported by ACR/NEMA DICOM 3.0, with contours created for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Trained medical professionals use Contour ProtégéAI as a tool to assist in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "Creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up and management.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Contour ProtégéAI as an accessory to MIM software, deployed on a remote server using the MIMcloud service for data management and transfer, or locally on the workstation or server running MIM software. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Contour ProtégéAI is an accessory to MIM software that automatically creates contours on medical images through the use of machine-learning algorithms." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer; or locally on the workstation or server running MIM software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, registered images, dose distributions, plans, measurements, or exported treatment-planning objects for professional review and approval.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Contour ProtégéAI as an accessory to MIM software, deployed on a remote server using the MIMcloud service for data management and transfer, or locally on the workstation or server running MIM software. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Contour ProtégéAI is an accessory to MIM software that automatically creates contours on medical images through the use of machine-learning algorithms." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer; or locally on the workstation or server running MIM software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes processing of CT and MR images as supported by ACR/NEMA DICOM 3.0, with contours created for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Trained medical professionals use Contour ProtégéAI as a tool to assist in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "Creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up and management.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
MIM Software's security page states SOC 2 Type 2 status, penetration testing and continuous vulnerability scanning of released products, coordinated vulnerability disclosure and a public security advisories page. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Current vendor material is product-family context for K231765 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
14Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor documentation, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, machine-learning contour creation for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segmentation across CT locations, and segmentation of the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Authorized purpose: Contour ProtégéAI creates machine-learning contours from CT and MR DICOM images to support quantitative analysis, adaptive therapy, radiotherapy planning, archiving, and follow-up; professionals must visualize, review, and edit contours, and the software is not intended to detect or contour lesions.
Modality
Radiotherapy Planning Imaging
Anatomy
Normal structures in labeled CT locations; prostate, seminal vesicles, and urethra on T2 MR
Authorized purpose: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
Modality
Radiotherapy Planning Imaging
Anatomy
Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.